🔗 Share this article

While America undertakes unprecedented revisions to its vaccination recommendations, one figure has surfaced somewhat surprisingly: Høeg, a Danish American sports medicine doctor and epidemiologist who rose to prominence by questioning coronavirus vaccinations during the pandemic and has concentrated on alleged fatalities following COVID-19 immunization in her short time at the FDA.

Planned Shifts to Childhood Vaccine Schedule

Public health authorities had intended to announce sweeping changes to the pediatric vaccine schedule earlier this month, aligning the US with the Danish vaccine program, according to reports – a substantial departure that would put the US at odds with a large portion of the international standard with insufficient data for public health gain. The announcement has been delayed until the next year.

Rather than the top vaccines chief, Høeg is scheduled to speak at the meeting. She was newly appointed acting director of the FDA’s CDER, the fifth person to run the center this calendar year.

A New Direction at the FDA

This interim role could signify a tighter collaboration between the pharmaceutical and biologics divisions as Dr. Høeg and Dr. Prasad consolidate power at the agency – and it signals a increased emphasis upon rolling back previously authorized immunizations at the FDA.

The new acting director has often pushed for ending specific pediatric vaccine recommendations in the US so as to align more similar to the Danish model, a nation with universal health coverage and a citizenry approximately the size of the state of Wisconsin.

To date statements, she has kept her attention on vaccination policy – traditionally the domain of Dr. Prasad, chief of the FDA’s CBER – instead of pharmaceutical oversight.

Questions Over Background

Dr. Høeg has no obvious background in pharmaceutical research, oversight or leadership, which has been typical for former directors of the CBER. She has been employed at the FDA as a key advisor to the agency head and the vaccine center since March.

“It seems she lacks to have any of the qualifications” for running the CDER, stated Jonathan Howard. “She lacks experience running a randomized controlled trial. She lacks experience in running a major agency. She has no expertise in drug approvals.”

Past directors of the center would “be deeply familiar with laws and regulations and the science of pharmaceutical innovation”, noted Janet Woodcock. “Objectively, she lacks the kind of background that previous people who led the center have had.”

The drug center has an enormous workload at the agency, she emphasized.

“The public just focuses on the new drug program, but the generic drug division authorizes thousands of generic medications. There is also a biologic copycat branch, non-prescription drug unit and other areas, and all of those need to be managed,” she noted. “The area you overlook, that’s the thing that I always told people is going to bite you.”

Furthermore, a major leadership component to the position, which manages in excess of 5,000 personnel. “It’s a massive management job, if you do it right,” she added.

Official Statement and Controversial Programs

In response to questions about Høeg’s qualifications and whether this assignment indicates more teamwork among regulatory chiefs on immunizations, a representative responded that the “inquiries are based on incorrect presumptions”.

“This background matches the functions of her position,” the spokesperson stated, pointing to the months Dr. Høeg spent advising the FDA commissioner on “pharmaceutical safety and oversight research, including computational safety modeling and immunization monitoring”.

As the temporary head, Høeg inherits the agency head's new fast-track approval initiative, a contentious expedited medication authorization process that allegedly worried her former heads. “How are these medications being selected for this voucher program? Who makes the decisions?” Dr. Howard said. “There’s a lot of lack of transparency happening at the FDA right now.”

In general, he stated, “the FDA looks to be trending towards more relaxed oversight of most medications, except for immunizations.”

Established Track Record on Vaccines

Regarding immunizations, Dr. Høeg has a more documented, if concerning, track record, Howard observe. She published a analysis using unconfirmed crowd-sourced reports to determine the rate of heart inflammation after Covid immunization. She consulted for the Florida chief medical officer Joseph Ladapo, who reportedly have altered data to indicate Covid vaccinations are pose a greater threat than they are.

Included in her “wish list” for the incoming federal leadership included altering rules for recently developed shots and ending “non-essential” immunizations, she stated following the vote on a podcast. At the agency, Dr. Høeg has allegedly suggested barring adolescent males from receiving Covid vaccinations.

“She is an all-around ideologue who commences with her preconceived notions and tailors the evidence to retrofit the evidence in a highly deceptive, dishonest way,” Howard stated.

Taking Control and a “Push for Payback”

Høeg aligned with other dissenters, {like|